DK2640742T3 - Samling af antistofsekvenser og disses anvendelser - Google Patents
Samling af antistofsekvenser og disses anvendelser Download PDFInfo
- Publication number
- DK2640742T3 DK2640742T3 DK11785411.7T DK11785411T DK2640742T3 DK 2640742 T3 DK2640742 T3 DK 2640742T3 DK 11785411 T DK11785411 T DK 11785411T DK 2640742 T3 DK2640742 T3 DK 2640742T3
- Authority
- DK
- Denmark
- Prior art keywords
- seq
- antibodies
- pairs
- germline
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (21)
1. Samling af syntetiske antistoffer eller funktionelle fragmenter deraf, hvor i det mindste 50% af antistoffeme eller funktionelle fragmenter omfatter variable tung kaede- og variable let kaede-par, hvor de strukturelle omrader af de naevnte variable tung kaede- og variable let kaede-par bestar af 25 eller Here kimbane-protein-sekvenser udvalgt blandt de variable tung kaede-par og variable let kaede-par udvisende sekven-serne saledes som defineret ifplge figurer 25-36: VH1-18 (SEQ ID NO: 204)/VKl-39 (SEQ ID NO: 236); VH1-18 (SEQ ID NO: 204)/VK3-15 (SEQ ID NO: 238); VH1-18 (SEQ ID NO: 204)/VK3-20 (SEQ ID NO: 239); VH1-46 (SEQ ID NO: 205)/VK3-15 (SEQ ID NO: 238); VH1-46 (SEQ ID NO: 205)/VLl-51 (SEQ ID NO: 252); VH1-46 (SEQ ID NO: 205)/VL3-21 (SEQ ID NO: 257); VH1-69*01 (SEQ ID NO: 206)/VLl-51 (SEQ ID NO: 252); VH3-07 (SEQ ID NO: 207)/VKl-12 (SEQ ID NO: 233); VH3-07 (SEQ ID NO: 207)/VKl-16 (SEQ ID NO: 234); VH3-07 (SEQ ID NO: 207)/VKl-27 (SEQ ID NO: 235); VH3-07 (SEQ ID NO: 207)/VKl-39 (SEQ ID NO: 236); VH3-07 (SEQ ID NO: 207)/VK3-15 (SEQ ID NO: 238); VH3-07 (SEQ ID NO: 207)/VLl-47 (SEQ ID NO: 251); VH3-07 (SEQ ID NO: 207)/VLl-51 (SEQ ID NO: 252); VH3-11 (SEQ ID NO: 208)/VKl-05 (SEQ ID NO: 230); VH3-11 (SEQ ID NO: 208)/VKl- 39 (SEQ ID NO: 236); VH3-11 (SEQ ID NO: 208)/VK3-15 (SEQ ID NO: 238); VH3-11 (SEQ ID NO: 208)/VLl-40 (SEQ ID NO: 2 50); VH3-11 (SEQ ID NO: 208)/VLl-47 (SEQ ID NO: 251); VH3-11 (SEQ ID NO: 208)NL1-51 (SEQ ID NO: 252); VH3-11 (SEQ ID NO: 208)/VL2-23 (SEQ ID NO: 255); VH3-15 (SEQ ID NO: 209)/VKl- 05 (SEQ ID NO: 230); VH3-15 (SEQ ID NO: 209)/VKl-06 (SEQ ID NO: 231); VH3- 15 (SEQ ID NO: 209)/VKl-12 (SEQ ID NO: 233); VH3-15 (SEQ ID NO: 209)/VKl- 16 (SEQ ID NO: 234); VH3-15 (SEQ ID NO: 209)/VKl-27 (SEQ ID NO: 235); VH3-15 (SEQ ID NO: 209)/VK3-ll (SEQ ID NO: 237); VH3-15 (SEQ ID NO: 209)/VLl- 40 (SEQ ID NO: 250); VH3-15 (SEQ ID NO: 209)/VLl-47 (SEQ ID NO: 251); VH3-15 (SEQ ID NO: 209)/VLl-51 (SEQ ID NO: 252); VH3-15 (SEQ ID NO: 209)/VL2- 14 (SEQ ID NO: 254); VH3-21 (SEQ ID NO: 210)/VK1-12 (SEQ ID NO: 233); VH3-21 (SEQ ID NO: 210)/VKl-27 (SEQ ID NO: 235); VH3-21 (SEQ ID NO: 210)/VL2-11 (SEQ ID NO: 253); VH3-23 (SEQ ID NO: 21Q/VK1-39 (SEQ ID NO: 236); VH3-23 (SEQ ID NO: 211)/VK3-15 (SEQ ID NO: 238); VH3-23 (SEQ ID NO: 21Q/VL2-23 (SEQ ID NO: 255); VH3-23 (SEQ ID NO: 211)/VL3-1 (SEQ ID NO: 256); VH3-30 (SEQ ID NO: 212)/VK3-20 (SEQ ID NO: 239); VH3-53 (SEQ ID NO: 213)/VK3- 15 (SEQ ID NO: 238); VH3-53 (SEQ ID NO: 213)/VL2-11 (SEQ ID NO: 253); VH3-74 (SEQ ID NO: 214)/VKl-05 (SEQ ID NO: 230); VH3-74 (SEQ ID NO: 214)/VK1- 06 (SEQ ID NO: 231); VH3-74 (SEQ ID NO: 214)/VK1-12 (SEQ ID NO: 2 33); VH3-74 (SEQ ID NO: 214)/VKl-27 (SEQ ID NO: 235); VH3-74 (SEQ ID NO: 214) /VK3-20 (SEQ ID NO: 239); VH3-74 (SEQ ID NO: 214)/VL1-51 (SEQ ID NO: 252); VH5-51 (SEQ ID NO: 215)/VKl-39 (SEQ ID NO: 236); VH5-51 (SEQ ID NO: 215) /VLl-40 (SEQ ID NO: 250); VH5-51 (SEQ ID NO: 215)/VL1-51 (SEQ ID NO: 252); VH6-1 (SEQ ID NO: 216)/VKl-09 (SEQ ID NO: 232); VH6-1 (SEQ ID NO: 216) /VK3-15 (SEQ ID NO: 238); VH6-1 (SEQ ID NO: 216)/VK3-20 (SEQ ID NO: 239) and VH6-1 (SEQ ID NO: 216)/VL1-51 (SEQ ID NO: 252).
2. Samling af syntetiske antistoffer eller funktionelle fragmenter deraf if0lge krav 1, hvor de strukturelle omrader af de variable tung kaede- og variable let kaede-par bestar af 30 eller Here kimbane-protein-sekvenser udvalgt blandt de variable tung kaede- og variable let kaede-par udvisende sekvenserne saledes som defineret if0lge figurer 25-36: VH1-18 (SEQ ID NO: 204)/VKl-39 (SEQ ID NO: 236); VH1-18 (SEQ ID NO: 204) /VK3-15 (SEQ ID NO: 238); VH1-18 (SEQ ID NO: 204)/VK3-20 (SEQ ID NO: 239); VH1-46 (SEQ ID NO: 205)/VK3-15 (SEQ ID NO: 238); VH1-46 (SEQ ID NO: 205) /VLl-51 (SEQ ID NO: 252); VH1-46 (SEQ ID NO: 205)/VL3-21 (SEQ ID NO: 257); VH1-69*01 (SEQ ID NO: 206)/VLl-51 (SEQ ID NO: 252); VH3-07 (SEQ ID NO: 207)/VKl-12 (SEQ ID NO: 233); VH3-07 (SEQ ID NO: 207)/VKl-16 (SEQ ID NO: 234); VH3-07 (SEQ ID NO: 207)/VKl-27 (SEQ ID NO: 235); VH3-07 (SEQ ID NO: 207)/VKl-39 (SEQ ID NO: 236); VH3-07 (SEQ ID NO: 207)/VK3-15 (SEQ ID NO: 238); VH3-07 (SEQ ID NO: 207)/VLl-47 (SEQ ID NO: 251); VH3-07 (SEQ ID NO: 207)/VLl-51 (SEQ ID NO: 252); VH3-11 (SEQ ID NO: 208)/VKl-05 (SEQ ID NO: 230); VH3-11 (SEQ ID NO: 208)/VKl-39 (SEQ ID NO: 236); VH3-11 (SEQ ID NO: 208)/VK3-15 (SEQ ID NO: 238); VH3-11 (SEQ ID NO: 208)/VLl-40 (SEQ ID NO: 250); VH3-11 (SEQ ID NO: 208)/VLl-47 (SEQ ID NO: 251); VH3-11 (SEQ ID NO: 208)/VLl-51 (SEQ ID NO: 252); VH3-11 (SEQ ID NO: 208)/VL2-23 (SEQ ID NO: 255); VH3-15 (SEQ ID NO: 209)/VKl-05 (SEQ ID NO: 230); VH3-15 (SEQ ID NO: 209)/VKl-06 (SEQ ID NO: 231); VH3-15 (SEQ ID NO: 209)/VKl-12 (SEQ ID NO: 233); VH3-15 (SEQ ID NO: 209)/VKl-16 (SEQ ID NO: 234); VH3-15 (SEQ ID NO: 209)/VKl-27 (SEQ ID NO: 235); VH3-15 (SEQ ID NO: 209)/VK3-ll (SEQ ID NO: 237); VH3-15 (SEQ ID NO: 209)/VLl-40 (SEQ ID NO: 250); VH3-15 (SEQ ID NO: 209)/VLl-47 (SEQ ID NO: 251); VH3-15 (SEQ ID NO: 209)/VLl-51 (SEQ ID NO: 252); VH3-15 (SEQ ID NO: 209)/VL2-14 (SEQ ID NO: 254); VH3-21 (SEQ ID NO: 210)/VK1-12 (SEQ ID NO: 233); VH3-21 (SEQ ID NO: 210)/VKl-27 (SEQ ID NO: 235); VH3-21 (SEQ ID NO: 210)/VL2-11 (SEQ ID NO: 253); VH3-23 (SEQ ID NO: 211)/VKl-39 (SEQ ID NO: 236); VH3-23 (SEQ ID NO: 211)/VK3-15 (SEQ ID NO: 238); VH3-23 (SEQ ID NO: 211)/VL2-23 (SEQ ID NO: 255); VH3-23 (SEQ ID NO: 211)/VL3-1 (SEQ ID NO: 256); VH3-30 (SEQ ID NO: 212)/VK3-20 (SEQ ID NO: 239); VH3-53 (SEQ ID NO: 213)/VK3-15 (SEQ ID NO: 238); VH3-53 (SEQ ID NO: 213)/VL2-11 (SEQ ID NO: 253); VH3-74 (SEQ ID NO: 214)/VKl-05 (SEQ ID NO: 230); VH3-74 (SEQ ID NO: 214)/VKl-06 (SEQ ID NO: 231); VH3-74 (SEQ ID NO: 214)/VK1-12 (SEQ ID NO: 233); VH3-74 (SEQ ID NO: 214)/VKl-27 (SEQ ID NO: 235); VH3-74 (SEQ ID NO: 214)/VK3-20 (SEQ ID NO: 239); VH3-74 (SEQ ID NO: 214)/VL1-51 (SEQ ID NO: 252); VH5-51 (SEQ ID NO: 215)/VKl-39 (SEQ ID NO: 236); VH5-51 (SEQ ID NO: 215)/VLl-40 (SEQ ID NO: 250); VH5-51 (SEQ ID NO: 215)/VL1-51 (SEQ ID NO: 252); VH6-1 (SEQ ID NO: 216)/VKl-09 (SFQ ID NO: 232); VH6-1 (SEQ ID NO: 216)/VK3-15 (SEQ ID NO: 238); VH6-1 (SEQ ID NO: 216)/VK3-20 (SEQ ID NO: 239) and VH6-1 (SEQ ID NO: 216)/VL1-51 (SEQ ID NO: 252).
3. Samling if0lge et hvilket som heist af de foregaende krav, hvor de strukturelle omrader af de variable tung kaede- og variable let kaede-par bestar af kimbane-protein-sekvenser udvalgt blandt de variable tung kaede- og variable let kaede-par udvisende sekvenserne saledes som defineret if0lge figurer 25-36: VH1-18 (SEQ ID NO: 204)/VK3-20 (SEQ ID NO: 239); VH1-46 (SEQ ID NO: 205)/VK3-15 (SEQ ID NO: 238); VH1-46 (SEQ ID NO: 205)/VLl-51 (SEQ ID NO: 252); VH1-69*01 (SEQ ID NO: 206)/VLl-51 (SEQ ID NO: 252); VH3-07 (SEQ ID NO: 207)/VKl-12 (SEQ ID NO: 233); VH3-07 (SEQ ID NO: 207)/VKl-27 (SEQ ID NO: 235); VH3-07 (SEQ ID NO: 207)/VK3-15 (SEQ ID NO: 238); VH3-07 (SEQ ID NO: 207)/VLl-47 (SEQ ID NO: 251); VH3-07 (SEQ ID NO: 207)/VLl-51 (SEQ ID NO: 252); VH3-11 (SEQ ID NO: 208)/VLl-40 (SEQ ID NO: 250); VH3-11 (SEQ ID NO: 208)/VLl-47 (SEQ ID NO: 251); VH3-11 (SEQ ID NO: 208)/VLl-51 (SEQ ID NO: 252); VH3-11 (SEQ ID NO: 208)/VL2-23 (SEQ ID NO: 255); VH3-15 (SEQ ID NO: 209)/VKl-05 (SEQ ID NO: 230); VH3-15 (SEQ ID NO: 209)/VKl-06 (SEQ ID NO: 231); VH3-15 (SEQ ID NO: 209)/VKl-12 (SEQ ID NO: 233); VH3-15 (SEQ ID NO: 209)/VKl-27 (SEQ ID NO: 235); VH3-15 (SEQ ID NO: 209)/VK3-ll (SEQ ID NO: 237); VH3-15 (SEQ ID NO: 209)/VLl-51 (SEQ ID NO: 252); VH3-21 (SEQ ID NO: 210)/VK1-12 (SEQ ID NO: 233); VH3-23 (SEQ ID NO: 21Q/VK1-39 (SEQ ID NO: 236); VH3-23 (SEQ ID NO: 21Q/VK3-15 (SEQ ID NO: 238); VH3-23 (SEQ ID NO: 211)/VL2-23 (SEQ ID NO: 255); VH3-23 (SEQ ID NO: 211)/VL3-1 (SEQ ID NO: 256); VH3-53 (SEQ ID NO: 213)/VK3-15 (SEQ ID NO: 238); VH3-53 (SEQ ID NO: 213)/VL2-11 (SEQ ID NO: 253); VH3-74 (SEQ ID NO: 214)/VKl-05 (SEQ ID NO: 230); VH3-74 (SEQ ID NO: 214)/VKl-06 (SEQ ID NO: 231); VH3-74 (SEQ ID NO: 214)/VK1-12 (SEQ ID NO: 233); VH3-74 (SEQ ID NO: 214)/VK3-20 (SEQ ID NO: 239); VH5-51 (SEQ ID NO: 215)/VKl-39 (SEQ ID NO: 236); VH5-51 (SEQ ID NO: 215)/VLl-40 (SEQ ID NO: 250); VH5-51 (SEQ ID NO: 215)/VL1-51 (SEQ ID NO: 252); VH6-1 (SEQ ID NO: 216)/VKl-09 (SEQ ID NO: 232); VH6-1 (SEQ ID NO: 216)/VK3-20 (SEQ ID NO: 239) and VH6-1 (SEQ ID NO: 216)/VL1-51 (SEQ ID NO: 252).
4. Samling af syntetiske antistoffer eller funktionelle fragmenter deraf if0lge krav 3, hvor de strukturelle omrader af de variable tung kaede- og variable let kaede-par bestar af kimbane-protein-sekvenser af de variable tung kaede- og variable let kaede-par udvi-sende sekvenseme saledes som defineret if0lge figurer 25-36: VH1-18 (SEQ ID NO: 204)/VK3-20 (SEQ ID NO: 239); VH1-46 (SEQ ID NO: 205)/VK3-15 (SEQ ID NO: 238); VH1-46 (SEQ ID NO: 205)/VLl-51 (SEQ ID NO: 252); VH1-69*01 (SEQ ID NO: 206)/VLl-51 (SEQ ID NO: 252); VH3-07 SEQ ID NO: 207)/VKl-12 (SEQ ID NO: 233); VH3-07 (SEQ ID NO: 207)/VKl-27 (SEQ ID NO: 235); H3 07 (SEQ ID NO: 207)/VK3-15 (SEQ ID NO: 238); VH3-07 (SEQ ID NO: 207)/VLl-47 (SEQ ID NO: 251); VH3-07 (SEQ ID NO: 207)/VLl-51 (SEQ ID NO: 252); VH3-11 (SEQ ID NO: 208)/VLl-40 (SEQ ID NO: 250); VH3-11 (SEQ ID NO: 208)/VLl-47 (SEQ ID NO: 251); VH3-11 (SEQ ID NO: 208)/VLl-51 (SEQ ID NO: 252); VH3-11 (SEQ ID NO: 208)/VL2-23 (SEQ ID NO: 255); VH3-15 (SEQ ID NO: 209)/VKl-05 SEQ ID NO: 230); VH3-15 (SEQ ID NO: 209)/VKl-06 (SEQ ID NO: 231); VH3-15 (SEQ ID NO: 209)/VKl-12 (SEQ ID NO: 233); VH3-15 (SEQ ID NO: 209)/VKl-27 (SEQ ID NO: 235); VH3-15 (SEQ ID NO: 209)/VK3-ll (SEQ ID NO: 237); VH3-15 (SEQ ID NO: 209)/VLl-51 (SEQ ID NO: 252); VH3-21 (SEQ ID NO: 210)/VK1-12 (SEQ ID NO: 233); VH3-23 (SEQ ID NO: 21Q/VK3-15 (SEQ ID NO: 238); VH3-53 (SEQ ID NO: 213)/VK3-15 (SEQ ID NO: 238); VH3-53 (SEQ ID NO: 213)/VL2-11 (SEQ ID NO: 253); VH3-74 (SEQ ID NO: 214)/VKl-05 (SEQ ID NO: 230); VH3-74 (SEQ ID NO: 214)/VKl-06 (SEQ ID NO: 231); VH3-74 (SEQ ID NO: 214)/VK1-12 (SEQ ID NO: 233); VH3-74 (SEQ ID NO: 214)/VK3-20 (SEQ ID NO: 239); VH5-51 (SEQ ID NO: 215)/VKl-39 (SEQ ID NO: 236); VH5-51 (SEQ ID NO: 215)/VLl-40 (SEQ ID NO: 250); VH5-51 (SEQ ID NO: 215)/VL1-51 (SEQ ID NO: 252); VH6-1 (SEQ ID NO: 216)/VKl-09 (SEQ ID NO: 232); VH6-1 (SEQ ID NO: 216)/VK3-20 (SEQ ID NO: 239) and VH6-1 (SEQ ID NO: 216)/VL1-51 (SEQ ID NO: 252).
5. Samling if0lge et hvilket som heist af de forudgaende krav, hvor de naevnte antistoffer eller funktionelle fragmenter deraf omfatter et eller Here komplementaritet- bestemmende omrader bestaende af kimbane-protein-sekvenser fra de respektive variable tung kaede- og variable let kaede-par.
6. Samling ifplge et hvilket som heist af de forudgaende krav, hvor de naevnte anti-stoffer eller funktionelle fragmenter deraf omfatter CDRl-omrader bestaende af kim-bane-protein-sekvenser fra de respektive variable tung kaede- og variable let kaede-par.
7. Samling ifplge et hvilket som heist af de forudgaende krav, hvor de naevnte anti-stoffer eller funktionelle fragmenter deraf omfatter CDR2-omrader bestaende af kim-bane-protein-sekvenser fra de respektive variable tung kaede- og variable let kaede-par.
8. Samling il'olge et hvilket som heist af de forudgaende krav, hvor de naevnte anti-stoffer eller funktionelle fragmenter deraf omfatter et eller Here komplementaritet-bestemmende omrader omfattende aminosyre-modifikationer, der fjerner potentielle steder med post-translatoriske modifikationer.
9. Samling il'olge krav 8, hvor de naevnte antistoffer eller funktionelle fragmenter deraf omfatter et eller Here tung kaede komplementaritet-bestemmende omrader omfattende de komplementaritet-bestemmende omrade-sekvenser fra de respektive tung kaeder an fort il'olge fig. 34-36.
10. Samling il'olge krav 9, hvor de naevnte antistoffer eller funktionelle fragmenter deraf omfatter HCDRl-omrader fra det respektive HCDRl-omrade an fort il'olge fig. 34.
11. Samling il'olge krav 9 eller 10, hvor de naevnte antistoffer eller funktionelle fragmenter deraf omfatter HCDR2-omrader fra det respektive HCDR2-omrade an fort ifplge fig. 35.
12. Samling il'olge et hvilket som heist af de forudgaende krav, hvor de naevnte antistoffer eller funktionelle fragmenter deraf omfatter et FR4-omrade udvalgt fra gruppen bestaende af JH4, JkI og .1 λ2/3 sekvenserne deraf er defineret il'olge fig. 40.
13. Samling il'olge et hvilket som heist af de forudgaende krav, hvor de naevnte antistoffer eller funktionelle fragmenter deraf omfatter et diversificeret HCDR3-omrade.
14. Samling if0lge et hvilket som heist af de forudgaende krav, hvor de naevnte anti-stoffer eller funktionelle fragmenter deraf omfatter et diversificeret LCDR3-omrade.
15. Samling if0lge et hvilket som heist af de forudgaende krav, hvor samlingen omfatter i det mindste 1 x 104 antistoffer eller funktionelle fragmenter deraf.
16. Samling if0lge et hvilket som heist af de forudgaende krav, hvor de naevnte antistoffer er udvalgt fra gruppeme bestaende af menneskelig IgGl, IgG2, IgG3, IgG4, IgA, IgE, IgM og IgD.
17. Samling if0lge et hvilket som heist af de forudgaende krav, hvor de naevnte funktionelle fragmenter af de naevnte antistoffer er udvalgt fra gruppen bestaende af Fab, F(ab’)2, Fab’, Fv og scFv.
18. Samling af nukleinsyrer, som koder en samling af antistoffer eller funktionelle fragmenter deraf ifplge et hvilket som heist af de forudgaende krav.
19. Vektor omfattende samlingen af nukleinsyrer if0lge krav 18.
20. Rekombinant vaertscelle omfattende nukleinsyrerne if0lge krav 18 eller vektoren ifplgekrav 19.
21. Fremgangsmade til identificering af et for et antigen specifikt antistof eller anti-stof-fragment omfattende: (a) etablering af beiwingskontakt for antigenet med en samling af antistoffer eller funktionelle fragmenter deraf ifplge krav 1, og (b) valg af et eller Here antistoffer eller antistof-fragmenter, som binder til det naevnte antigen.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41536710P | 2010-11-19 | 2010-11-19 | |
EP10191910 | 2010-11-19 | ||
US201161494452P | 2011-06-08 | 2011-06-08 | |
PCT/EP2011/070473 WO2012066129A1 (en) | 2010-11-19 | 2011-11-18 | A collection and methods for its use |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2640742T3 true DK2640742T3 (da) | 2018-12-03 |
Family
ID=44041472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11785411.7T DK2640742T3 (da) | 2010-11-19 | 2011-11-18 | Samling af antistofsekvenser og disses anvendelser |
Country Status (18)
Country | Link |
---|---|
US (3) | US8367586B2 (da) |
EP (1) | EP2640742B1 (da) |
JP (1) | JP6253986B2 (da) |
KR (1) | KR101938021B1 (da) |
CN (1) | CN103237809B (da) |
AU (1) | AU2011331129B2 (da) |
CA (1) | CA2816558C (da) |
DK (1) | DK2640742T3 (da) |
ES (1) | ES2696548T3 (da) |
HR (1) | HRP20181811T1 (da) |
IL (1) | IL226364B (da) |
MX (1) | MX353795B (da) |
NZ (1) | NZ609707A (da) |
PL (1) | PL2640742T3 (da) |
RU (1) | RU2603080C2 (da) |
SG (2) | SG10201509257VA (da) |
WO (1) | WO2012066129A1 (da) |
ZA (1) | ZA201303566B (da) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102993305B (zh) | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | 人源抗人表皮生长因子受体抗体及其编码基因与应用 |
SG11201601272YA (en) * | 2013-09-18 | 2016-03-30 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
US10684289B2 (en) | 2013-12-09 | 2020-06-16 | Adimab, Llc | Polyclonal mixtures of antibodies, and methods of making and using them |
CA3233584A1 (en) * | 2013-12-27 | 2015-07-02 | Chugai Seiyaku Kabushiki Kaisha | Method for purifying antibody having low isoelectric point |
CU20180087A7 (es) | 2016-02-19 | 2019-03-04 | Galapagos Nv | Anticuerpos para il-17-c |
EP3538552B1 (en) | 2016-11-14 | 2023-09-13 | MorphoSys AG | Fab molecules with a rodent hinge region and a non-rodent ch1 region |
WO2019099454A2 (en) | 2017-11-15 | 2019-05-23 | Philippe Valadon | Highly functional antibody libraries |
WO2019219765A1 (en) | 2018-05-16 | 2019-11-21 | Morphosys Ag | Antibodies targeting glycoprotein vi |
KR102115300B1 (ko) * | 2018-06-01 | 2020-05-26 | 재단법인 목암생명과학연구소 | 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법 |
AU2021274883A1 (en) | 2020-05-20 | 2022-12-01 | Centre National De La Recherche Scientifique - Cnrs - | Synthetic single domain library |
WO2021250017A1 (en) | 2020-06-08 | 2021-12-16 | Immundiagnostik Ag | Improved method and test system for in-vitro determination of drug antibodies in blood |
CA3189473A1 (en) | 2020-09-24 | 2022-03-31 | Andreas Bultmann | Novel human antibodies binding to human cd3 epsilon |
WO2023180346A1 (en) | 2022-03-22 | 2023-09-28 | Morphosys Ag | Deimmunized antibodies specific for cd3 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US6291161B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
EP0478627A4 (en) | 1989-05-16 | 1992-08-19 | William D. Huse | Co-expression of heteromeric receptors |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
US6291160B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
DE4002897A1 (de) | 1990-02-01 | 1991-08-08 | Behringwerke Ag | Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken") |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
WO1992015678A1 (en) | 1991-03-01 | 1992-09-17 | Stratagene | Pcr generated dicistronic dna molecules for producing antibodies |
DK1279731T3 (da) | 1991-03-01 | 2007-09-24 | Dyax Corp | Fremgangsmåde til udvikling af bindende miniproteiner |
DK0597960T3 (da) | 1991-08-10 | 1999-09-13 | Medical Res Council | Behandling af cellepopulationer |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
ES2313867T3 (es) | 1991-12-02 | 2009-03-16 | Medical Research Council | Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos. |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US5395750A (en) | 1992-02-28 | 1995-03-07 | Hoffmann-La Roche Inc. | Methods for producing proteins which bind to predetermined antigens |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5855885A (en) | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
CA2175579A1 (en) | 1993-10-26 | 1995-05-04 | Chang Yi Wang | Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics |
US20010049107A1 (en) | 1994-01-31 | 2001-12-06 | Boston University | Polyclonal antibody libraries |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
DK0859841T3 (da) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
US6828422B1 (en) | 1995-08-18 | 2004-12-07 | Morphosys Ag | Protein/(poly)peptide libraries |
GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
WO1999006587A2 (en) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
EP1157041B1 (en) | 1999-03-01 | 2005-06-01 | Genentech, Inc. | Antibodies for cancer therapy and diagnosis |
PT1144607E (pt) | 1999-07-20 | 2009-04-22 | Morphosys Ag | Novos métodos para apresentar (poli)peptídeos/ proteínas em partículas bacteriofágicas através de ligações dissulfureto |
IL136459A0 (en) | 2000-05-30 | 2001-06-14 | Galim Galil Immunology Ltd | Antibody library |
EP1360288B1 (en) | 2000-12-18 | 2011-02-16 | Dyax Corp. | Focused libraries of genetic packages |
US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
ATE434040T1 (de) | 2001-10-01 | 2009-07-15 | Dyax Corp | Mehrkettige eukaryontische display-vektoren und deren verwendungen |
GB0130267D0 (en) | 2001-12-19 | 2002-02-06 | Neutec Pharma Plc | Focussed antibody technology |
AU2002360068B2 (en) | 2001-12-21 | 2009-09-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method for cloning of variable domain sequences |
US7244592B2 (en) | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
CA2505849C (en) | 2002-07-30 | 2013-11-05 | Morphosys Ip Gmbh | Novel tricistronic vectors and uses therefor |
US8557743B2 (en) | 2002-09-05 | 2013-10-15 | Dyax Corp. | Display library process |
GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
EP2325339A3 (en) | 2003-09-09 | 2011-11-02 | Integrigen, Inc. | Methods and compositions for generation of germline human antibody genes |
TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
WO2005094159A2 (en) | 2003-11-12 | 2005-10-13 | Oncomab Gmbh | Methods of identifying neoplasm-specific antibodies and uses thereof |
EP1718765A2 (en) | 2004-01-26 | 2006-11-08 | Isis Innovation Limited | Molecular analysis |
ATE505727T1 (de) | 2004-05-26 | 2011-04-15 | Fraunhofer Ges Forschung | Isolation allergen-spezifischer immunoglobulin- gene aus humanen b-zellen von atopikern |
WO2006014498A2 (en) | 2004-07-06 | 2006-02-09 | Bioren, Inc. | Universal antibody libraries |
WO2006028987A2 (en) | 2004-09-02 | 2006-03-16 | Bioarray Solutions Ltd. | Nucleic acid amplification with integrated multiplex detection |
US20060078898A1 (en) | 2004-10-12 | 2006-04-13 | Curry Bo U | Methods and compositions for reducing label variation in array-based comparative genome hybridization assays II |
US20080003617A1 (en) * | 2004-12-20 | 2008-01-03 | Xiaomin Fan | Methods for the identification and the isolation of epitope specific antibodies |
US8551920B2 (en) | 2005-02-01 | 2013-10-08 | Morpho Sys AG | Libraries and methods for isolating antibodies |
RU2311927C2 (ru) * | 2005-08-15 | 2007-12-10 | Федеральное государственное унитарное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" | КОМБИНАТОРНАЯ ФАГМИДНАЯ БИБЛИОТЕКА ОДНОЦЕПОЧЕЧНЫХ АНТИТЕЛ ЧЕЛОВЕКА, ОБОГАЩЕННАЯ АНТИТЕЛАМИ ПРОТИВ ВИРУСА ОСПОВАКЦИНЫ, РЕКОМБИНАНТНАЯ ФАГМИДНАЯ ДНК pHEN-2A8, СОДЕРЖАЩАЯ УНИКАЛЬНЫЙ ГЕН ОДНОЦЕПОЧЕЧНОГО АНТИТЕЛА ЧЕЛОВЕКА, СПОСОБНОГО НЕЙТРАЛИЗОВАТЬ ВИРУС ОСПОВАКЦИНЫ И ВИРУС ОСПЫ КОРОВ, И ИСКУССТВЕННОЕ ОДНОЦЕПОЧЕЧНОЕ АНТИТЕЛО ЧЕЛОВЕКА 2A8, СПОСОБНОЕ НЕЙТРАЛИЗОВАТЬ ВИРУС ОСПОВАКЦИНЫ И ВИРУС ОСПЫ КОРОВ |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
NZ569359A (en) | 2005-12-20 | 2011-11-25 | Morphosys Ag | Novel collection of HCDR3 regions and uses therefor |
WO2007130520A2 (en) | 2006-05-04 | 2007-11-15 | Abmaxis Inc. | Cross-species and multi-species display systems |
EP2190987B1 (en) | 2007-08-21 | 2012-11-14 | MorphoSys AG | Methods for the formation of disulphide bonds |
US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
CN101970730A (zh) | 2007-12-19 | 2011-02-09 | 森托科尔奥索生物科技公司 | 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法 |
EP2088432A1 (en) | 2008-02-11 | 2009-08-12 | MorphoSys AG | Methods for identification of an antibody or a target |
US9873957B2 (en) | 2008-03-13 | 2018-01-23 | Dyax Corp. | Libraries of genetic packages comprising novel HC CDR3 designs |
EP2100970B1 (en) | 2008-03-13 | 2017-05-10 | National Institute of Immunology | Ig genes specific oligonucleotides and uses thereof |
EP2331570B1 (en) | 2008-09-10 | 2014-08-27 | Philochem AG | Display library for antibody selection |
EP2356270B1 (en) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
WO2010130824A2 (en) * | 2009-05-15 | 2010-11-18 | Morphosys Ag | Collections and uses thereof |
DK2435568T3 (da) * | 2009-05-29 | 2014-09-08 | Morphosys Ag | Samling af syntetiske antistoffer til behandling af sygdom |
DK2528944T3 (da) | 2010-01-29 | 2015-09-14 | Morphosys Ag | Kombinatoriske gnaver-antistofbiblioteker |
-
2011
- 2011-11-18 RU RU2013126025/10A patent/RU2603080C2/ru active
- 2011-11-18 KR KR1020137015575A patent/KR101938021B1/ko active IP Right Grant
- 2011-11-18 US US13/299,367 patent/US8367586B2/en active Active
- 2011-11-18 AU AU2011331129A patent/AU2011331129B2/en active Active
- 2011-11-18 JP JP2013539286A patent/JP6253986B2/ja active Active
- 2011-11-18 WO PCT/EP2011/070473 patent/WO2012066129A1/en active Application Filing
- 2011-11-18 SG SG10201509257VA patent/SG10201509257VA/en unknown
- 2011-11-18 DK DK11785411.7T patent/DK2640742T3/da active
- 2011-11-18 ES ES11785411T patent/ES2696548T3/es active Active
- 2011-11-18 CN CN201180055462.8A patent/CN103237809B/zh active Active
- 2011-11-18 EP EP11785411.7A patent/EP2640742B1/en active Active
- 2011-11-18 US US13/884,975 patent/US8728981B2/en active Active
- 2011-11-18 PL PL11785411T patent/PL2640742T3/pl unknown
- 2011-11-18 MX MX2013005614A patent/MX353795B/es active IP Right Grant
- 2011-11-18 SG SG2013030085A patent/SG189950A1/en unknown
- 2011-11-18 NZ NZ609707A patent/NZ609707A/en not_active IP Right Cessation
- 2011-11-18 CA CA2816558A patent/CA2816558C/en active Active
-
2013
- 2013-05-16 IL IL226364A patent/IL226364B/en active IP Right Grant
- 2013-05-16 ZA ZA2013/03566A patent/ZA201303566B/en unknown
-
2014
- 2014-04-02 US US14/242,906 patent/US9541559B2/en active Active
-
2018
- 2018-10-31 HR HRP20181811TT patent/HRP20181811T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2011331129A1 (en) | 2013-05-23 |
WO2012066129A1 (en) | 2012-05-24 |
IL226364A0 (en) | 2013-07-31 |
CA2816558A1 (en) | 2012-05-24 |
NZ609707A (en) | 2014-12-24 |
SG189950A1 (en) | 2013-06-28 |
US20130236902A1 (en) | 2013-09-12 |
CN103237809B (zh) | 2016-09-07 |
US9541559B2 (en) | 2017-01-10 |
ES2696548T3 (es) | 2019-01-16 |
IL226364B (en) | 2020-11-30 |
RU2603080C2 (ru) | 2016-11-20 |
RU2013126025A (ru) | 2014-12-27 |
US20120129717A1 (en) | 2012-05-24 |
ZA201303566B (en) | 2014-07-30 |
JP2014500725A (ja) | 2014-01-16 |
KR20140015274A (ko) | 2014-02-06 |
US8728981B2 (en) | 2014-05-20 |
EP2640742A1 (en) | 2013-09-25 |
CN103237809A (zh) | 2013-08-07 |
HRP20181811T1 (hr) | 2018-12-28 |
JP6253986B2 (ja) | 2017-12-27 |
AU2011331129B2 (en) | 2016-10-06 |
EP2640742B1 (en) | 2018-08-15 |
MX353795B (es) | 2018-01-30 |
MX2013005614A (es) | 2013-11-21 |
SG10201509257VA (en) | 2015-12-30 |
US8367586B2 (en) | 2013-02-05 |
KR101938021B1 (ko) | 2019-01-11 |
CA2816558C (en) | 2020-12-29 |
US20140206575A1 (en) | 2014-07-24 |
PL2640742T3 (pl) | 2019-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2640742T3 (da) | Samling af antistofsekvenser og disses anvendelser | |
US10647757B2 (en) | Collection and methods for its use | |
US11702463B2 (en) | Canine antibody libraries |